Skip to main content
. 2022 Oct 17;3(10):1211–1227. doi: 10.1038/s43018-022-00438-2

Extended Data Fig. 9. Clinical relevance of ALK activation, p-Y19 CDK9 expression and HR factors in ovarian cancer.

Extended Data Fig. 9

(a) Characterization of p-ALK antibody in cytospin slides. Data are representative of two repeats with similar results. (b) A peptide competition assay was carried out to characterize p-Y19 CDK9 antibody by IHC staining of tumor tissue from ovarian cancer patient. Different peptides as indicated were used to incubate with p-Y19 CDK9 antibody. Data are representative of two repeats with similar results. (c) Clinical relevance of p-ALK and p-Y19 CDK9 in human ovarian TMA analysis (Biomax,US, #OV809b). (d–f) Representative images (d) and quantification of IHC staining for the correlation between HR factors (RAD51, CtIP, or p-RPA) and p-ALK (e) or p-Y19 CDK9 (f), by human ovarian tissue microarray analysis (Biomax,US, #OV809b). Bar, 20 µm. Statistical analysis was carried out using the two-side Fisher’s exact test. The experiment was performed an additional time with similar results.